vs

Side-by-side financial comparison of Cognizant (CTSH) and TE Connectivity (TEL). Click either name above to swap in a different company.

Cognizant is the larger business by last-quarter revenue ($5.3B vs $4.7B, roughly 1.1× TE Connectivity). TE Connectivity runs the higher net margin — 16.1% vs 12.2%, a 3.9% gap on every dollar of revenue. On growth, TE Connectivity posted the faster year-over-year revenue change (21.7% vs 4.9%). Cognizant produced more free cash flow last quarter ($781.0M vs $607.0M). Over the past eight quarters, TE Connectivity's revenue compounded faster (8.5% CAGR vs 5.8%).

Cognizant Technology Solutions Corporation is an American multinational information technology consulting and outsourcing company originally founded in India. It is headquartered in Teaneck, New Jersey, United States. Cognizant is part of the NASDAQ-100 and trades under CTSH. It was founded in Chennai, India, as an in-house technology unit of Dun & Bradstreet in 1994, and started serving external clients in 1996.

TE Connectivity plc is an American-Irish domiciled technology company that designs and manufactures electrical and electronic components. It serves several industries, including automotive, aerospace, defense, medical, and energy.

CTSH vs TEL — Head-to-Head

Bigger by revenue
CTSH
CTSH
1.1× larger
CTSH
$5.3B
$4.7B
TEL
Growing faster (revenue YoY)
TEL
TEL
+16.8% gap
TEL
21.7%
4.9%
CTSH
Higher net margin
TEL
TEL
3.9% more per $
TEL
16.1%
12.2%
CTSH
More free cash flow
CTSH
CTSH
$174.0M more FCF
CTSH
$781.0M
$607.0M
TEL
Faster 2-yr revenue CAGR
TEL
TEL
Annualised
TEL
8.5%
5.8%
CTSH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CTSH
CTSH
TEL
TEL
Revenue
$5.3B
$4.7B
Net Profit
$648.0M
$750.0M
Gross Margin
37.2%
Operating Margin
16.0%
20.6%
Net Margin
12.2%
16.1%
Revenue YoY
4.9%
21.7%
Net Profit YoY
18.7%
42.0%
EPS (diluted)
$1.35
$2.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTSH
CTSH
TEL
TEL
Q4 25
$5.3B
$4.7B
Q3 25
$5.4B
$4.7B
Q2 25
$5.2B
$4.5B
Q1 25
$5.1B
$4.1B
Q4 24
$5.1B
$3.8B
Q3 24
$5.0B
$4.1B
Q2 24
$4.8B
$4.0B
Q1 24
$4.8B
$4.0B
Net Profit
CTSH
CTSH
TEL
TEL
Q4 25
$648.0M
$750.0M
Q3 25
$274.0M
$663.0M
Q2 25
$645.0M
$638.0M
Q1 25
$663.0M
$13.0M
Q4 24
$546.0M
$528.0M
Q3 24
$582.0M
$276.0M
Q2 24
$566.0M
$573.0M
Q1 24
$546.0M
$541.0M
Gross Margin
CTSH
CTSH
TEL
TEL
Q4 25
37.2%
Q3 25
35.0%
Q2 25
35.3%
Q1 25
35.2%
Q4 24
35.5%
Q3 24
34.0%
Q2 24
34.8%
Q1 24
34.4%
Operating Margin
CTSH
CTSH
TEL
TEL
Q4 25
16.0%
20.6%
Q3 25
16.0%
19.3%
Q2 25
15.6%
18.9%
Q1 25
16.7%
18.1%
Q4 24
14.8%
18.0%
Q3 24
14.6%
16.0%
Q2 24
14.6%
19.0%
Q1 24
14.6%
17.4%
Net Margin
CTSH
CTSH
TEL
TEL
Q4 25
12.2%
16.1%
Q3 25
5.1%
14.0%
Q2 25
12.3%
14.1%
Q1 25
13.0%
0.3%
Q4 24
10.7%
13.8%
Q3 24
11.5%
6.8%
Q2 24
11.7%
14.4%
Q1 24
11.5%
13.6%
EPS (diluted)
CTSH
CTSH
TEL
TEL
Q4 25
$1.35
$2.53
Q3 25
$0.56
$2.23
Q2 25
$1.31
$2.14
Q1 25
$1.34
$0.04
Q4 24
$1.10
$1.75
Q3 24
$1.17
$0.96
Q2 24
$1.14
$1.86
Q1 24
$1.10
$1.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTSH
CTSH
TEL
TEL
Cash + ST InvestmentsLiquidity on hand
$1.9B
$1.3B
Total DebtLower is stronger
Stockholders' EquityBook value
$15.0B
$13.0B
Total Assets
$20.7B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTSH
CTSH
TEL
TEL
Q4 25
$1.9B
$1.3B
Q3 25
$2.4B
$1.3B
Q2 25
$1.8B
$672.0M
Q1 25
$2.0B
$2.6B
Q4 24
$2.2B
$1.3B
Q3 24
$2.0B
$1.3B
Q2 24
$2.2B
$1.5B
Q1 24
$2.2B
$1.2B
Stockholders' Equity
CTSH
CTSH
TEL
TEL
Q4 25
$15.0B
$13.0B
Q3 25
$14.9B
$12.6B
Q2 25
$15.3B
$12.4B
Q1 25
$14.9B
$12.1B
Q4 24
$14.4B
$12.4B
Q3 24
$14.5B
$12.4B
Q2 24
$13.9B
$12.6B
Q1 24
$13.5B
$12.4B
Total Assets
CTSH
CTSH
TEL
TEL
Q4 25
$20.7B
$25.6B
Q3 25
$20.1B
$25.1B
Q2 25
$20.2B
$24.9B
Q1 25
$20.0B
$23.7B
Q4 24
$20.0B
$22.4B
Q3 24
$20.2B
$22.9B
Q2 24
$18.6B
$22.9B
Q1 24
$18.4B
$22.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTSH
CTSH
TEL
TEL
Operating Cash FlowLast quarter
$858.0M
$865.0M
Free Cash FlowOCF − Capex
$781.0M
$607.0M
FCF MarginFCF / Revenue
14.6%
13.0%
Capex IntensityCapex / Revenue
1.4%
5.5%
Cash ConversionOCF / Net Profit
1.32×
1.15×
TTM Free Cash FlowTrailing 4 quarters
$2.6B
$3.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTSH
CTSH
TEL
TEL
Q4 25
$858.0M
$865.0M
Q3 25
$1.2B
$1.4B
Q2 25
$398.0M
$1.2B
Q1 25
$400.0M
$653.0M
Q4 24
$920.0M
$878.0M
Q3 24
$847.0M
$1.0B
Q2 24
$262.0M
$1.0B
Q1 24
$95.0M
$710.0M
Free Cash Flow
CTSH
CTSH
TEL
TEL
Q4 25
$781.0M
$607.0M
Q3 25
$1.2B
$1.1B
Q2 25
$331.0M
$957.0M
Q1 25
$323.0M
$423.0M
Q4 24
$837.0M
$673.0M
Q3 24
$791.0M
$829.0M
Q2 24
$183.0M
$857.0M
Q1 24
$16.0M
$543.0M
FCF Margin
CTSH
CTSH
TEL
TEL
Q4 25
14.6%
13.0%
Q3 25
21.4%
24.2%
Q2 25
6.3%
21.1%
Q1 25
6.3%
10.2%
Q4 24
16.5%
17.5%
Q3 24
15.7%
20.4%
Q2 24
3.8%
21.5%
Q1 24
0.3%
13.7%
Capex Intensity
CTSH
CTSH
TEL
TEL
Q4 25
1.4%
5.5%
Q3 25
1.2%
5.7%
Q2 25
1.3%
5.1%
Q1 25
1.5%
5.6%
Q4 24
1.6%
5.3%
Q3 24
1.1%
5.2%
Q2 24
1.6%
3.7%
Q1 24
1.7%
4.2%
Cash Conversion
CTSH
CTSH
TEL
TEL
Q4 25
1.32×
1.15×
Q3 25
4.48×
2.14×
Q2 25
0.62×
1.86×
Q1 25
0.60×
50.23×
Q4 24
1.68×
1.66×
Q3 24
1.46×
3.78×
Q2 24
0.46×
1.76×
Q1 24
0.17×
1.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTSH
CTSH

Health Sciences$1.4B25%
Financial Services$1.1B21%
Consulting And Technology Services$944.0M18%
Productsand Resources$921.0M17%
Outsourcing Services$677.0M13%
Transaction Or Volume Based$308.0M6%

TEL
TEL

Automotive Industry End Market$1.9B40%
Digital Data Networks$707.0M15%
Automation And Connected Living Industry End Market$549.0M12%
Energy Industry End Market$406.0M9%
Aerospace Defense And Marine Industry End Market$381.0M8%
Commercial Transportation Industry End Market$370.0M8%
Sensors Industry End Market$212.0M5%
Medical Industry End Market$159.0M3%

Related Comparisons